Silva Pharmaceuticals Cash Flow Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-145.41	-132.95	-64.48	33.08	102.26	119.85
Depreciation & Amortization	56.29	59.11	60.45	65.93	68.12	70.73
Other Amortization	0.25	0.19	0.14	0.15	0.17	0.16
Other Operating Activities	9.04	8.77	7.06	-1.86	-11.12	3.29
Change in Accounts Receivable	35.06	26.51	3.19	-1.71	14.6	-8.79
Change in Inventory	54.23	50.19	0.52	-11.43	-18.11	-19.8
Change in Accounts Payable	3.61	2.81	0.17	0.09	0.64	-0.29
Change in Other Net Operating Assets	-4.74	-1.07	-3.63	-14.15	4.3	-5.76
Operating Cash Flow	8.32	13.56	3.42	70.1	160.85	159.4
Operating Cash Flow Growth	-	296.57%	-95.12%	-56.42%	0.91%	5.83%
Capital Expenditures	-4.99	-7.07	-32.99	-86.81	-177.64	-77.18
Investment in Securities	-52.63	24.77	63.92	72.32	-13.38	-8.63
Investing Cash Flow	-57.63	17.7	30.93	-14.49	-191.02	-85.82
Short-Term Debt Issued	-	-	-	-	61.87	2.46
Total Debt Issued	1.04	-	-	-	61.87	2.46
Short-Term Debt Repaid	-	-19.49	-8.13	-35.17	-	-
Long-Term Debt Repaid	-	-1.7	-2.24	-3.2	-6.18	-6.49
Total Debt Repaid	-9.37	-21.19	-10.37	-38.37	-6.18	-6.49
Net Debt Issued (Repaid)	-8.33	-21.19	-10.37	-38.37	55.69	-4.04
Common Dividends Paid	-9.86	-9.99	-13.93	-25.03	-47.75	-47.3
Financing Cash Flow	-18.19	-31.18	-24.3	-63.4	7.94	-51.34
Net Cash Flow	-67.49	0.08	10.05	-7.78	-22.24	22.25
Free Cash Flow	3.33	6.49	-29.57	-16.7	-16.8	82.22
Free Cash Flow Margin	0.93%	1.69%	-4.93%	-2.33%	-2.16%	10.29%
Free Cash Flow Per Share	0.02	0.05	-0.22	-0.12	-0.12	0.60
Cash Interest Paid	4.86	4.11	3.63	2.73	4.06	1.74
Cash Income Tax Paid	4.47	5.06	11.76	20.28	26.23	29.26
Levered Free Cash Flow	52.56	59.92	-1.92	-28.2	-48.45	53.24
Unlevered Free Cash Flow	55.76	62.73	0.82	-25.94	-45.5	54.98
Change in Working Capital	88.15	78.44	0.26	-27.19	1.43	-34.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.